Cargando…
Uninterrupted Continuation of VV-ECMO Without Anticoagulation for 44 Days in COVID-19 ARDS: A Precarious Quandary
Venovenous extracorporeal membrane oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population who do not respond to conventional medical therapy suffering from severe acute respiratory distress syndrome (ARDS) due to COVID-19. This therapy necessitates the utiliza...
Autores principales: | Patel, Sankalp P., Solomon, Brian J., Pascotto, Robert D., D'Orazio, Stephen E., Navas, Elsy V., Cubeddu, Robert J., Cudemus, Gaston A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994674/ https://www.ncbi.nlm.nih.gov/pubmed/35545457 http://dx.doi.org/10.1053/j.jvca.2022.04.006 |
Ejemplares similares
-
Right Ventricular Failure Manifesting in Corona Virus Disease 2019 Acute Respiratory Distress Syndrome: A Call to Transition from Venovenous Extracorporeal Membranous Oxygenation to Right Ventricular Assist Device Extracorporeal Membranous Oxygenation
por: Patel, Sankalp P., et al.
Publicado: (2022) -
Successful use of VV-ECMO in a pregnant patient with severe ARDS()()()
por: Carlier, Laurence, et al.
Publicado: (2019) -
Early vvECMO implantation may be associated with lower mortality in ARDS
por: Rosenberger, Peter, et al.
Publicado: (2023) -
VV-ECMO usage in ARDS due to COVID-19: Clinical, practical and ethical considerations
por: Hoyler, Marguerite M., et al.
Publicado: (2020) -
(591) Prolonged V.v.-Ecmo for Covid-19 Ards with Lung Recovery
por: Beckett, A., et al.
Publicado: (2023)